BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $9.31 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2018-03-12
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2017 was $9.31M, a 45.92% increase from fiscal 2016.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2016 was $6.38M, a 42.03% increase from fiscal 2015.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2015 was $4.49M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2017-12-31 | $9.31M 10-K · filed 2018-03-12 |
| 2016-12-31 | $6.38M 10-K · filed 2018-03-12 |
| 2015-12-31 | $4.49M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |